Barinthus Biotherapeutics (NASDAQ:BRNS) Announces Quarterly Earnings Results

Barinthus Biotherapeutics (NASDAQ:BRNS) announced its quarterly earnings results on Wednesday. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.23, RTT News reports. The company had revenue of $14.97 million during the quarter. During the same period in the prior year, the company earned ($0.37) earnings per share.

Barinthus Biotherapeutics Trading Up 0.4 %

Shares of Barinthus Biotherapeutics stock traded up $0.01 during mid-day trading on Thursday, reaching $1.49. 7,475 shares of the stock were exchanged, compared to its average volume of 23,586. Barinthus Biotherapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $4.39. The company has a market cap of $58.61 million, a price-to-earnings ratio of -0.89 and a beta of -0.59. The firm has a 50-day simple moving average of $1.29 and a 200 day simple moving average of $1.58.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Barinthus Biotherapeutics in a research report on Thursday, September 26th. Alliance Global Partners cut their price objective on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating for the company in a research report on Tuesday, August 13th.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.